Semaglutide vs Retatrutide
Bottom line
Semaglutide is the established, FDA-approved GLP-1 drug — a single-receptor agonist with a deep evidence base, an oral option, and cardiovascular-outcomes data. Retatrutide is an investigational triple agonist (GIP/GLP-1/glucagon) posting the largest weight-loss figures yet reported (~28–30% in Phase 3), but it is not approved, has no long-term safety record, and isn’t legitimately available. One is a prescribable medicine today; the other is the leading next-generation candidate still in trials. The headline figures come from separate trials, not a head-to-head.
At a glance
| Semaglutide | Retatrutide | |
|---|---|---|
| Class | GLP-1 receptor agonist (mono-agonist) | Triple GIP/GLP-1/glucagon (GCGR) agonist |
| Primary use | T2D; obesity; CV risk reduction; MASH (2025) | Investigational — obesity, T2D, MASLD, OA-related (trials) |
| Evidence level | Approved — SUSTAIN, STEP, SELECT Phase 3 programs | Clinical — Phase 2 complete; Phase 3 TRIUMPH reporting (investigational) |
| Typical weight loss | ~14.9% at 2.4 mg over 68 wks (STEP-1) | ~28.3% at 12 mg over 80 wks; ~30.3% at 104 wks (BMI ≥35 extension) — TRIUMPH-1 |
| Half-life | ~7 days | ~6 days |
| Route | Subcutaneous (Ozempic, Wegovy) · Oral (Rybelsus; oral Wegovy 25 mg) | Subcutaneous only |
| FDA / legal status | FDA-approved (multiple indications) | Not approved — investigational; submission anticipated late 2026/early 2027 |
Key Differences
- Mechanism — one target vs three. Semaglutide activates only the GLP-1 receptor. Retatrutide adds GIP and, distinctively, glucagon (GCGR) agonism — the glucagon arm is thought to raise energy expenditure and promote hepatic fat oxidation on top of appetite and glycemic effects, a mechanism absent from GLP-1 mono-agonists and even from dual agonists like Tirzepatide.
- Weight-loss magnitude. Retatrutide’s trial figures (~28.3% at 80 weeks, up to ~30.3% in a BMI-≥35 extension; 45.3% of the 12 mg arm lost ≥30%) are the highest reported for an obesity drug, approaching bariatric-surgery territory. Semaglutide reaches ~15% at 2.4 mg in STEP-1. These are cross-trial comparisons — there is no published head-to-head.
- Evidence maturity — the decisive gap. Semaglutide is approved, with large completed programs and a cardiovascular-outcomes trial (SELECT, ~20% MACE reduction) plus 2025 approvals for MASH and an oral obesity formulation. Retatrutide is investigational: Phase 3 topline is positive but long-term safety and final regulatory status are not yet established.
- Glucagon trade-off. Retatrutide’s glucagon arm can theoretically oppose glycemic lowering and is associated with a dose-dependent heart-rate increase under monitoring in trials. Semaglutide’s single-pathway profile is far better characterized.
- Availability & route. Semaglutide is a prescription medicine with subcutaneous and oral forms. Retatrutide has no approved product — anything sold now is unverified gray-market material carrying the highest sourcing risk in this category. Both are once-weekly injectables where injected.
Which Is Which
- An actual treatment today is semaglutide (or another approved agent) under a clinician — prescribable, quality-assured, with the strongest cardiovascular evidence in the class.
- Retatrutide is not a current option outside an authorized clinical trial; its standout efficacy is real in the data but does not change that it is unapproved, of unestablished long-term safety, and unavailable as a legitimate medicine.
- For those tracking the field, retatrutide is the leading next-generation candidate, with a regulatory submission anticipated late 2026/early 2027 — so it is not expected to be marketed in the near term.
- Both are clinician-level decisions; neither is a “cycle” compound. See Fat Loss and Metabolic & GLP-1 for class context, Tirzepatide vs Retatrutide and Semaglutide vs Tirzepatide for the other head-to-heads, and Evidence Grading Explained for the tiers.
Not medical advice — See Disclaimer.
References
- Wilding J.P.H. et al. (2021). “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP-1). New England Journal of Medicine.
- Lincoff A.M. et al. (2023). “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes” (SELECT). New England Journal of Medicine.
- Jastreboff A.M. et al. (2023). “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine.
- Eli Lilly and Company (2025–2026). TRIUMPH-1 Phase 3 topline results — ~28.3% at 12 mg/80 wks; 45.3% achieving ≥30%; investor release.
← Stacks · Home Educational information only — not medical advice. See Disclaimer.